Citigroup
BCRX icon

Citigroup’s BioCryst Pharmaceuticals BCRX Stock Holding History

Citigroup’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-95,000
Closed -$950K – 6013
2026
Q2 		$950K Hold
95,000
– – ﹤0.01% 3484
2026
Q1 		$904K Buy
95,000
+94,800
+47,400% +$736K ﹤0.01% 3178
2025
Q4 		$1.56K Buy
+200
New +$1.45K ﹤0.01% 5493
2023
Q4 		– Sell
-39,900
Closed -$282K – 5702
2023
Q3 		$282K Hold
39,900
– – ﹤0.01% 3450
2023
Q2 		$281K Buy
+39,900
New +$320K ﹤0.01% 3712
2021
Q1 		– Sell
-19,900
Closed -$148K – 6273
2020
Q4 		$148K Buy
19,900
+18,000
+947% +$92.8K ﹤0.01% 5220
2020
Q3 		$7K Sell
1,900
-300
-14% -$1.29K ﹤0.01% 6813
2020
Q2 		$10K Buy
2,200
+200
+10% +$799 ﹤0.01% 7037
2020
Q1 		$4K Sell
2,000
-1,200
-38% -$3.3K ﹤0.01% 7299
2019
Q4 		$11K Buy
+3,200
New +$8.05K ﹤0.01% 7168
2019
Q3 		– Sell
-6,200
Closed -$23K – 7686
2019
Q2 		$23K Buy
6,200
+5,600
+933% +$33.7K ﹤0.01% 7004
2019
Q1 		$5K Sell
600
-13,100
-96% -$112K ﹤0.01% 7411
2018
Q4 		$111K Sell
13,700
-4,000
-23% -$31.1K ﹤0.01% 5568
2018
Q3 		$135K Buy
17,700
+6,700
+61% +$45K ﹤0.01% 5613
2018
Q2 		$63K Buy
11,000
+8,000
+267% +$44K ﹤0.01% 6100
2018
Q1 		$14K Buy
+3,000
New +$15.4K ﹤0.01% 6905
2017
Q4 		– Sell
-1,700
Closed -$9K – 7548
2017
Q3 		$9K Sell
1,700
-2,600
-60% -$13.3K ﹤0.01% 6715
2017
Q2 		$24K Sell
4,300
-1,600
-27% -$9.7K ﹤0.01% 6186
2017
Q1 		$50K Sell
5,900
-400
-6% -$2.78K ﹤0.01% 5690
2016
Q4 		$40K Buy
+6,300
New +$32.8K ﹤0.01% 6240

Other funds holding BCRX

Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 24.61% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Candriam SCA
Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $348B AUM 26.9% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
OP Asset Management
OP Asset Management Helsinki $11.8B AUM 34.59% 1-Year Est. Return
IMC Chicago
IMC Chicago Chicago, Illinois $483B AUM 41.26% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
Nan Fung Trinity
Nan Fung Trinity Central, Hong Kong, Hong Kong $1.04B AUM 32.17% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return

Citigroup's BCRX Position: Q3 2026 in Review

Citigroup reduced its BioCryst Pharmaceuticals (BCRX) stake by 51% in Q3 2026, selling an estimated $1.72M and leaving 177,184 shares worth $1.48M. The position accounts for ﹤0.01% of the portfolio, ranked #3045.

Citigroup first reported a position in BCRX in Q2 2013 and has held it in 54 quarters since. The position peaked at $11.6M in Q1 2024. 116 funds tracked by Wall St. Rank hold BCRX as of Q3 2026.

  • Citigroup held 177,184 shares of BioCryst Pharmaceuticals worth $1.48M as of Q3 2026.
  • Citigroup sold 183,005 BioCryst Pharmaceuticals shares in Q3 2026, an estimated $1.72M.
  • BioCryst Pharmaceuticals made up ﹤0.01% of Citigroup's portfolio in Q3 2026, its #3045 holding.
  • Citigroup first reported a position in BioCryst Pharmaceuticals in Q2 2013 and has held it in 54 quarters since.
  • Citigroup's BioCryst Pharmaceuticals position peaked at $11.6M in Q1 2024.
  • 116 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q3 2026.

Based on Citigroup's 13F filing for Q3 2026, filed 4 Nov 2026.